# EDGAR Filing Document

**Accession Number:** 0001689375
**File Stem:** 0001104659-26-063325
**Filing Date:** 2026-5
**Character Count:** 64730
**Document Hash:** 0aac22f009ec1f143e962ac708446b09
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-063325.hdr.sgml**: 20260519

**ACCESSION NUMBER**: 0001104659-26-063325

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 63

**CONFORMED PERIOD OF REPORT**: 20260518

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260519

**DATE AS OF CHANGE**: 20260518

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Entrada Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001689375
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 813983399
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40969
- **FILM NUMBER:** 26995369

**BUSINESS ADDRESS:**
- **STREET 1:** ONE DESIGN CENTER PLACE
- **STREET 2:** SUITE 17-500
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 857-305-1825

**MAIL ADDRESS:**
- **STREET 1:** ONE DESIGN CENTER PLACE
- **STREET 2:** SUITE 17-500
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CycloPorters, Inc.
- **DATE OF NAME CHANGE:** 20161104

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 18, 2026**

**ENTRADA THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40969** | **81-3983399** |
| **(State or other jurisdiction** | **(Commission** | **(I.R.S. Employer** |
| **of incorporation)** | **File Number)** | **Identification No.)** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**One Design Center Place**<br> **Suite 17-500** |  |
| &nbsp;&nbsp;**Boston, MA** | &nbsp;&nbsp;**02210** |
| &nbsp;&nbsp;(Address of principal executive offices) | &nbsp;&nbsp;(Zip Code) |

---

**Registrant's telephone number, including area code: (857) 520-9158**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br> Symbol(s)** | **Name of each exchange<br> on which registered** |
| **Common Stock, $0.0001 par value per share** | **TRDA** | **The Nasdaq Global Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 7.01 Regulation FD Disclosure.** 

On May 18, 2026, Entrada Therapeutics, Inc. updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the updated corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated by reference herein.

The information in Item 7.01 of this Current Report, including the accompanying Exhibit 99.1, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of such section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibit relating to Item 7.01 of this Current Report shall be deemed to be furnished and not filed:

[99.1](tm2614944d1_ex99-1.htm) [Corporate Presentation of Entrada Therapeutics, Inc., dated May 2026.](tm2614944d1_ex99-1.htm) <br> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
|  | Entrada Therapeutics, Inc. |
| Date: May 18, 2026 | /s/ Dipal Doshi |
|  | Dipal Doshi |
|  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img001.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meet Andrew and JJ, living with Duchenne muscular dystrophy Corporate Presentation May 2026 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img002.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclaimer May 2026 2 This presentation has been prepared by Entrada Therapeutics, Inc. ("Entrada") and shall not constitute an offer to sell or a solicitation of an offer to buy securities or an invitation or inducement to engage in investment activity nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of such securities under the securities law of any such jurisdiction. Before you invest in any securities of Entrada, you should read any documents Entrada has filed with the SEC for more complete information about Entrada and the offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. This presentation contains express and implied forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding Entrada's strategy, future operations, prospects and plans, objectives of management, the validation, differentiation and superiority of Entrada's approach and EEV platform and its ability to provide a potential best-in-class outcomes in high unmet need diseases, expectations regarding Entrada's Phase 1/2 MAD clinical study of ENTR-601-44, including the completion of the open-label period by year-end 2026 and the reporting, translatability, and ability to achieve a clinically meaningful effect from additional metrics data, including 10-meter walk/run, stride velocity 95th centile, 4-stair climb, north star ambulatory, and performance upper limb, the translatability of dystrophin concentrations and exon skipping based on juvenile NHP data, the timing of competitive data from Cohort 2 by year-end 2026, with expected higher levels of plasma and muscle exposure (linear or better), substantially higher dystrophin levels, increases in muscle function and continued functional response over time, with the timing of Cohort 3 to follow, expectations regarding the data from the clinical study of ENTR-601-44, including expected results such as higher dystrophin restoration and positive safety data, expectations regarding muscle regeneration, muscle stabilization, and greater strength in patients as measured by Time to Rise velocity, expectations regarding the connection between EEV-PMO uptake in satellite cells and muscle regeneration, speed and durability of functional improvement, expectations of lower risk of anti-drug antibody response and lower cost of goods from EEV-PMO conjugates, translatability of current data to de-risk Entrada's DMD clinical portfolio, support dose escalations, and its ability to support U.S. Accelerated Approval, expectations regarding Entrada's Phase 1/2 MAD clinical study of ENTR-601-45 and the timing of first-in-class data from Cohort 1 in mid-2026, expectations regarding the timing to market of ENTR-601-45 and it's potential best-in-class clinical profile, expectations regarding regulatory filings in the EU for the planned Phase 1/2 MAD clinical study of ENTR-601-50, expectations regarding the global regulatory filings for the planned clinical study of ENTR-601-51, the ability to recruit for and complete global Phase 2 clinical studies of ENTR-601-44, ENTR-601-45, ENTR-601-50 and ENTR-601-51 and to obtain U.S. Accelerated Approval and/or full approval for each program, the ability of EEV therapies to provide a 25-50-fold improvement in endosomal escape and lower whole drug requirements compared to antibody-based therapies, the ability to continue to expand and develop additional therapeutic programs and modalities, including further exon skipping programs, the potential therapeutic benefits of Entrada's EEV product candidates and the ability to advance therapeutic candidates in indications beyond neuromuscular disease, including but not limited to ocular disease, expectations regarding the timing of nomination of a second clinical candidate for inherited retinal disease in the second half of 2026, the continued development and advancement of ENTR-601-44, -45, -50 and -51 for the potential treatment of DMD and ENTR-801 for the potential treatment of Usher syndrome type 2A and the partnered product candidate VX-670 for the potential treatment of DM1, expectations regarding the progress and success of Entrada's collaboration with Vertex, including expected proceeds from program milestones plus royalties and completion of the MAD portion of the global Phase 1/2 study of the VX-670 program and results shared in the second half of 2026, the size of the DMD market opportunity in the U.S., and the sufficiency of Entrada's cash resources into the third quarter of 2027, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "predict," "project," "potential," "should," or "would," or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Entrada may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities and the initiation and completion of preclinical studies and clinical studies; uncertainties as to the availability and timing of results from preclinical and clinical studies; the timing of and Entrada's ability to submit and obtain regulatory clearance and initiate clinical studies; whether results from preclinical studies or clinical studies will be predictive of the results of later preclinical studies and clinical studies; whether Entrada's cash resources will be sufficient to fund Entrada's foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Entrada's filings with the SEC, including Entrada's most recent Form 10-K and in subsequent filings Entrada may make with the SEC. In addition, the forward-looking statements included in this presentation represent Entrada's views as of the date of this presentation. Entrada anticipates that subsequent events and developments will cause its views to change. However, while Entrada may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Entrada's views as of any date subsequent to the date of this presentation. |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img003.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2026 is a transformational year for Entrada May 2026 Entrada is a clinical-stage biopharma company developing proprietary genetic medicines to deliver best-in-class outcomes in high unmet need diseases \*ELEVATE-44-201 Cohort 1, DMD: Duchenne muscular dystrophy; DM1: Myotonic dystrophy type 1; Cash runway based on current operating plans and ending cash, cash equivalents and marketable securities as of March 31, 2026. • 5 clinical-stage programs in DMD and DM1 • 4 clinical data catalysts in DMD and DM1 patients achieved or expected in 2026 • 2 development candidates in inherited retinal diseases projected by year-end 2026 • Cash runway into Q3 2027 • Up to $485 million in DM1 milestones, plus royalties associated with Vertex partnership • $5 billion U.S. DMD market, with limited competitive penetration; Untapped global markets • FDA Accelerated Approval strategy to be supported by Phase 1/2 data from ex-U.S. DMD studies • Proprietary and differentiated delivery and active moiety sequences in all candidate programs • Favorable safety data and early but compelling functional improvement results\* • Best-in-class preclinical data in all declared clinical and preclinical programs Deep pipeline with value inflection points in 2026 Differentiated programs in untapped markets Capitalized to realize value catalysts 3 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img004.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;May 2026 \*All references in this presentation regarding planned regulatory filings and clinical study designs are subject to ongoing discussion with regulatory authorities; DMD: Duchenne muscular dystrophy; DM1: Myotonic dystrophy type 1; SAD: Single ascending dose; MAD: Multiple ascending dose. ENTR-601-44 • Cohort 1 dosing complete; All patients transitioned to open-label dosing • Cohort 2 dose escalation cleared to initiate at 12 mg/kg and dosing ongoing • Cohort 1 open-label and Cohort 2 MAD data expected by year-end 2026 ENTR-601-45 • Cohort 1 data expected mid-2026 ENTR-601-50 and ENTR-601-51 • Additional regulatory filings expected following a review of data from the ongoing DMD clinical studies • Completed SAD portion of global Phase 1/2 study • MAD portion to evaluate safety and efficacy is ongoing • Vertex to share study results in H2 2026 • Partnership terms include up to $485 million in milestones, plus royalties Inherited Retinal Diseases • Nominated first ocular candidate, ENTR-801 for Usher syndrome type 2A • Second program in lead optimization; Candidate declaration in H2 2026 Additional Discovery Efforts • Expansion of neuromuscular and ocular franchises leveraging next-generation EEVs and oligonucleotides • Range of undisclosed diseases, targets and modalities Rapidly Expanding DMD Clinical Franchise Vertex Advancing VX-670 for the Treatment of DM1 Advancing Innovative Preclinical Pipeline 4 Clinical inflection points for ENTR-601-44, ENTR-601-45 and VX-670 in 2026; ENTR-601-44 safety data fundamentally de-risks the neuromuscular portfolio Multiple clinical milestones achieved or expected in 2026 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img005.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d Each target disease has a substantial patient population with a significant unmet medical need May 2026 Phase 1/2 ENTR-801: USH2A Undisclosed Undisclosed Duchenne Muscular Dystrophy (DMD) Inherited Retinal Diseases Myotonic Dystrophy Type 1 (DM1) – Partnered with ENTR-601-44 ENTR-601-45 ENTR-601-50 ENTR-601-51 VX-670 Preclinical Phase 2/3 5 Pipeline and Platform Expansion Phase 1/2 data from ex-U.S. DMD studies to support Accelerated Approval regulatory filings in the U.S. Advancing five fully owned programs and one partnered program |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img006.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Duchenne Muscular Dystrophy (DMD) |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img007.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entrada's DMD strategy is to de-risk a differentiated portfolio and commercially launch best-in-class drugs May 2026 7 • Novel EEV and PMO sequences • Best-in-class non-clinical data translated into compelling safety and functional data • Progenitor cell uptake supports regenerative potential, speed and durability of functional improvement • Lower whole drug exposure supports lower risk of anti-drug antibody response and lower cost of goods • Favorable ENTR-601-44 Phase 1 healthy volunteer safety profile • Favorable ENTR-601-44 Phase 1/2 patient safety data for Cohort 1 • Statistically significant improvement in functional benefit\* observed in ENTR-601-44 Cohort 1 • All neuromuscular programs leverage the same EEV • ENTR-601-44 Cohort 1 data de-risks the DMD franchise • Phase 1/2 data from ex-U.S. studies to support U.S. Accelerated Approval\*\* • ENTR-601-44 Cohort 1 open-label and Cohort 2 MAD expected to deliver competitive data by year-end 2026 • First-in-class clinical program in exon 45 projected to deliver Cohort 1 MAD data by mid-2026 Differentiated EEV Platform and Novel PMO Conjugates De-risked and Rapid Clinical Development Potential for "Best-in-class" Commercial Opportunities \*Time to Rise velocity (TTRV), nominal p-value, post hoc analysis; \*\*Accelerated Approval is subject to regulatory feedback; PMO: Phosphorodiamidate morpholino oligomer; Healthy volunteer may also be described as HNV (healthy normal volunteer). Three strategic pillars: Differentiation, de-risking and best-in-class opportunities |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img008.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entrada is developing genetic medicines to correct the mechanism of disease and slow, halt or reverse progression May 2026 8 ~8% ~9% ~4% ~15% The portfolio covers ~35% of the total population totaling ~11,500 patients in the U.S. and EU\* DMD Mutations and Tissues of Focus in the Entrada Portfolio PMO, phosphorodiamidate morpholino oligomer. Individuals with Duchenne Entrada Approach Pre-mRNA mRNA Protein With exon deletion, protein program is miscoded Reading frame disrupted and body reads STOP! Resultant mRNA sequence stops the production of functional dystrophin protein No Translation DMD Pre-mRNA mRNA Protein Treatment enables skipping of exon Reading frame restored Functional dystrophin protein is translated and muscle membrane regains integrity Translation Missing code Oligo blocks inclusion of an exon Splice modulation Entrada addresses mutations which result in a lack of dystrophin, muscle breakdown, progressive disability and death Entrada's Approach: Modulate RNA Splicing and Produce Functional Protein to Preserve and Rebuild Muscle ~35% = ~11,500 Patients\* Heart Diaphragm Skeletal muscle 44 45 50 51 \*Sub-mutation estimates rounded, from Bladen et al., HGVS Journal, January 2015; DMD population estimated to be ~7-8 per 100,000 males per Crisafulli et al., Orphanet J. Rare Disease, June 2020; Calculation based on estimates of U.S. and EU (defined as EU27 population). |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img009.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. Annual Market Opportunity $ Millions $0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000 May 2026 9 Entrada's DMD franchise is positioned to address ~1/3 of all U.S. DMD patients, representing a potential ~$5B annual market opportunity in the U.S. alone Entrada's DMD franchise unlocks a potential $5B U.S. market opportunity, with significant further upside ex-U.S. \*$1M per patient per year market price estimated based on Lin et al., Institute for Clinical and Economic Review, April 2022, Posner et al., Journal of Manag. Care and Spec. Pharm. 2025; \*\*Bladen et al., HGVS Journal, January 2015; Total U.S. DMD population estimated to be ~7-8 per 100,000 males (~13,800) per Crisafulli et al., Orphanet J. Rare Disease, June 2020. ~$5 Billion Annual U.S. Commercial Opportunity\* ENTR-601-44 ENTR-601-45 ENTR-601-50 ENTR-601-51 U.S. DMD Franchise Total ~$1.1B ~$1.3B ~$0.6B ~$1.9B ~$4.8B ~1,100 Patients ~1,250 Patients ~550 Patients ~1,900 Patients • Few available treatment options and limited competitive penetration to date • ~5,000 U.S. patients addressable with exon skipping therapies 44, 45, 50 and 51\*\* • ~6,500 European patients addressable with exon skipping therapies 44, 45, 50 and 51\*\* • Ex-U.S. market not factored into projections and represents further upside potential ~4,800 Patients |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img010.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ELEVATE-44-201 Cohort 1: Study Results Summary |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img011.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive summary and key takeaways ELEVATE-44-201 Cohort 1 results May 2026 • Favorable safety and tolerability profile at 6 mg/kg; All AEs were mild to moderate ▪ No reported SAEs nor AEs leading to discontinuation ▪ Renal markers within normal range and comparable to placebo • Functional benefit demonstrated at 6 mg/kg via Time to Rise and Time to Rise Velocity (TTR and TTRV) measures ▪ TTR is a secondary endpoint of the ELEVATE-44-201 study ▪ Cohort 1 resulted in a statistically significant\* impact on TTR and TTRV versus placebo ▪ TTRV levels were several fold above MCID after only 3 doses (127 days, 6 weeks after the last dose administered) • Mechanistic advantages support early functional benefit observations ▪ EEV-PMO uptake in satellite cells can lead to the proliferation, activation and asymmetric division which is the basis of muscle regeneration ▪ Continued benefit in muscle function expected in the open-label period of Cohort 1 and future Cohorts • Updated PK modeling, based on recently received juvenile NHP data, supports higher dystrophin in Cohorts 2 and 3 ▪ Due to lower plasma drug exposures, dystrophin levels in Cohort 1 were lower than predicted 11 AE: Adverse event; SAE: Serious adverse events TTR: Time to Rise; TTRV: Time to Rise velocity; 10MWR: 10-meter walk/run; MCID: Minimal clinically important difference; Pharmacokinetics may be abbreviated to PK and Pharmacodynamics may be abbreviated to PD; \*Wilcoxon rank-sum (one sided) test, nominal p-values, post hoc analysis. Early functional benefit response is compelling and statistically significant Cohort 1 achieved the objective of demonstrating safety/tolerability; Importantly, Cohort 1 achieved functional benefit at the lowest dose with dystrophin levels expected to increase in Cohorts 2 and 3 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img012.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ELEVATE-44-201 Cohort 1: Trial Design and Treatment Population |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img013.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;May 2026 13 \*Expansion cohort and potential for Accelerated Approval is subject to regulatory feedback; Global registration and approval will require Phase 3 studies to follow the Phase 1/2 studies; Phase 3 studies will likely include functional measures as the primary endpoint (U.S. confirmatory study/EU registrational study). Screening Double-Blind Period Open-Label Period Follow-up Period Up to 6 weeks 19 weeks 31 weeks 6 weeks N=24 participants across three cohorts, n=8 per cohort Within each cohort, randomization 3:1 (ENTR-601-44 to placebo) ✓ Cohort 1: 6 mg/kg or placebo • Cohort 2: 12 mg/kg or placebo • Cohort 3: ≤18 mg/kg or placebo x3 doses Days 1, 43 and 85 Muscle biopsy #2 Day 127 Part A Ambulatory participants with DMD who are exon 44 skipping amenable Muscle biopsy #1 Participants who complete Part A are able to continue into open-label period • Receive 6 doses of ENTR-601-44 at the level that was administered in participant's Part A cohort • Dosing initiated • Study blinded to end of open-label period Expansion Cohort ELEVATE-44-201 is a global, two-part, randomized, double-blind placebo-controlled Phase 1/2 study in ambulatory patients\* Primary objective: Safety and tolerability of ENTR-601-44 Secondary objectives: Evaluation of pharmacokinetics, exon skipping, dystrophin production and measures of function ENTR-601-44 • Cohort 2: 12 mg/kg or placebo ✓ Cohort 1: 6 mg/kg or placebo • Ongoing ✓ Complete ELEVATE-44-201 is designed to support U.S. Accelerated Approval and forms the basis of a global registrational program\* |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img014.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Demographics and baseline characteristics May 2026 ELEVATE-44-201 Placebo n=2 ENTR-601-44 6 mg/kg n=6 Age, mean 13.5 9.3 Body mass index, mean, kg/m2 17.96 20.00 Age at disease onset, mean, years 1.0 2.2 Corticosteroid use, n (%) 2 (100%) 6 (100%) Ambulatory, n (%) 2 (100%) 6 (100%) Baseline dystrophin 4.6% 4.0% • Baseline dystrophin levels seen in Cohort 1 were the lowest levels observed in recent Exon 44 studies • Higher levels of baseline dystrophin correlate to higher treatment responses and vice versa 14 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img015.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ELEVATE-44-201 Cohort 1: Safety Data  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img016.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Safety was consistent and unremarkable at the 6 mg/kg dose May 2026 ELEVATE-44-201 TEAE: Treatment emergent adverse event. 16 Participants with ≥1 TEAE, n (%) Placebo n=2 ENTR-601-44 6 mg/kg n=6 Any TEAE 2 (100%) 6 (100%) TEAEs related to study drug 1 (50%) 5 (83%) Serious TEAEs 0 0 TEAEs leading to study discontinuation 0 0 TEAEs leading to death 0 0 All TEAEs were mild to moderate • Headache was the most common study drug–related TEAE, reported in 50% of the treatment group and 50% of the placebo group • All events resolved • There were no serious TEAEs and no study discontinuation due to any causes • No hypomagnesemia or renal safety concerns were noted A highly favorable safety profile supports a de-risking of DMD programs |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img017.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;May 2026 Data from ELEVATE-44-201; eGFR: Estimated glomerular filtration rate; LLN: Lower limit of normal; ULN: Upper limit of normal; Serum creatinine reference range shown is 27–106 μmol/L and is dependent on age of the participant enrolled in Cohort 1; Serum creatinine is below normal in participants with DMD due to reduced muscle mass. ELEVATE-44-201 eGFR Serum Cystatin C Serum Magnesium Serum Creatinine Renal markers were within normal range and comparable to placebo 17 Renal marker results further de-risk current and future DMD programs and support dose escalation to drive a higher therapeutic index |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img018.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ELEVATE-44-201 Cohort 1: Functional Efficacy Data  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img019.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Functional benefit summary May 2026 • Time to Rise and Time to Rise Velocity are the first functional measurements to "move" • Functional benefit demonstrated via Time to Rise and Time to Rise Velocity measurements ▪ TTRV is a calculation based on TTR that minimizes any imputation, outliers and noise associated with TTR ▪ TTRV is a clinically significant and accepted regulatory endpoint ▪ Cohort 1 resulted in a statistically significant impact on TTRV versus placebo at levels several fold above MCID after only 3 doses (127 days, 6 weeks after the last dose administered) ▪ TTR and TTRV generally precede improvements in other functional measures (10MWR, etc.) • Positive trends observed in 10MWR and will be tracked and reported at the end of the open-label period (year-end 2026) • Additional metrics (e.g., 4SC) to be reported at the end of the open-label period (year-end 2026) 4SC: 4 stair climb. 19 Early functional benefit response is compelling and statistically significant Cohort 1 achieved functional benefit via statistically significant measurements in both TTR and TTRV; 10MWR trending favorably with additional metrics to be shared by year-end 2026 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img020.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Functional improvement The importance and meaning of Time to Rise velocity May 2026 20 Time to Rise, a secondary endpoint in this study, is a robust, prognostic factor that predicts disease progression; Time to Rise velocity reduces the impact of imputation, outliers and noise 1.Cicala et al., Italian DMD Network (WMS 2025); 2.McDonald et al., CINRG DNHS (PPMD 2021); NSAA: North Star Ambulatory Assessment. TTR baseline (seconds) TTR end of study (seconds) Improvement (seconds) TTRV calculation Δ TTRV (rises/sec) 6.0 3.89 2.11 1/3.89 – 1/6.0 = 0.257 – 0.167 +0.09 8.0 4.65 3.35 1/4.65 – 1/8.0 = 0.215 – 0.125 +0.09 10.0 5.26 4.74 1/5.26 – 1/10.0 = 0.190 – 0.100 +0.09 Explanation: A boy starting at a TTR of 6 seconds needs to improve by ~2 seconds to achieve +0.09 ΔTTRV, but a boy starting at a TTR of 10 seconds needs to improve by ~4.5 seconds for the same velocity change • TTR declines rapidly over time in patients with DMD and is an early prognostic factor for disease progression and loss of ambulation1 ▪ The largest absolute and proportional annual signal among functional measures and early prognostic factor for disease progression and loss of ambulation ▪ Robust, as rising from the floor depends on proximal strength and postural control, functions affected early in disease progression1 ▪ Precedes improvements in 4-stair climb or 10-meter walk test and less complicated than NSAA2 • TTRV is calculated as 1/TTR, expressed as rises/second and is designed to reduce the impact of outliers and imputed data (illustration at right) ▪ Handles the unable to perform problem by scoring that observation at zero avoiding arbitrary scoring ▪ Dampens clinically meaningless scoring noise between visits ▪ Compresses the long tail and produces a distribution that is much closer to normal, which matters for parametric statistics Illustrative Data and Representative Calculation of TTRV 1 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img021.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Functional cascade: TTR velocity is a robust indicator of treatment effect and the earliest measurement to move May 2026 21 Proximal functional measures, including TTR and 4SC, detect changes before composite/distal measures like PUL and NSAA; TTR and TTRV were statistically significant versus placebo in Cohort 1 Sources: Duong et al., J Neuromuscul Dis 2021;8(6):939–948; Gupta et al., PLOS ONE 2023; Rabbia et al., J Neuromuscul Dis 2024; EMA SV95C Qualification Opinion 2022; McDonald et al., Muscle Nerve 2013; Mercuri et al., NMD 2016; OLE: Open-label extension. Relevant Functional Readout ENTR-601-44 Cohort 1 detected a statistically significant TTRV signal at Day 127 (18 weeks) which is consistent with TTRV being the earliest timed function test to detect treatment effect 4SC Velocity 4 Stair Climb • Baseline not collected in Cohort 1 MAD; To be reported at the end of the open-label period 10MWR Velocity 10-Meter Walk/Run • Trend towards functional improvement in Cohort 1 MAD portion of the study; Will be assessed at the end of the open-label period SV95C Stride Velocity 95th Centile • Not collected during Cohort 1 MAD; To be reported at the end of the open-label period PUL 2.0 Performance Upper Limb • Less sensitive in ambulatory participants; To be reported at the end of the open-label period NSAA North Star Ambulatory • Composite measure; Will be assessed at the end of the open-label period TTR Velocity Time to Rise (TTSTAND) • Statistically significant improvement versus placebo demonstrated in Cohort 1 MAD portion of the study Status Of Functional Measure Collection and Readout MAD (18 weeks) Open-Label (~1 year) OL – OLE\* (≥1 year) Relevant Study Period |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img022.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disease-modifying functional benefit seen at lowest dose TTRV results May 2026 22 \*Analysis on TTRV versus placebo shown rather than TTR in order to maintain the study blind, Wilcoxon rank-sum (one sided) test, nominal p-values, post hoc analysis; MCID: "The Minimal Clinical Important Difference (MCID) in Annual Rate of Change of Timed Function Tests in Boys with DMD," Duong T, Canbek J, Birkmeier M, Nelson L, Siener C, Fernandez-Fernandez A, Henricson E, McDonald CM, Gordish-Dressman H and the CINRG-DNHS Investigators; Journal of Neuromuscular Diseases. 2021;8(6):939–948; Updated from previously disclosed topline data to reflect subsequently received information. 0 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.1 TTRV Improvement Versus Placebo MCID • TTR is a pre-specified secondary endpoint in the ELEVATE-44-201 study • Change in TTR and in TTRV was seen across the majority of treated participants, irrespective of age • The mean change in TTRV versus placebo was 0.09, ~3.5x higher than the MCID threshold of 0.023 • End of Cohort 1 dystrophin levels correlated with the end of Cohort 1 TTRV, suggesting that dystrophin production may have crossed a critical threshold for functional improvement • The magnitude of the overall response supports the hypothesis that Cohort 1's functional benefit represents a true drug-related effect • In addition, 10MWR also demonstrated positive trends versus placebo Change in Time to Rise velocity Versus Placebo (rises/second) TTRV Improvement Versus Placebo\* p<0.05\* ~3.5x MCID Significant improvements in TTR and TTRV were observed\*; TTRV is a widely accepted Phase 3 endpoint in DMD, with good statistical properties for evaluating motor function in patients Key Takeaways |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img023.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ENTR-601-44 delivered a differentiated impact on TTRV TTRV is a validated registrational endpoint May 2026 23 Sources: \*VISION-DMD (JAMA 2022) registrational study; DELIVER (Dyne Company presentation); EMBARK (FDA Decisional Memo 2024); ENTR-601-44 (Cohort 1); No head-to-head trials have been conducted; Cross-trial comparisons may not be reliable based on differences in study designs, compound formulation and mechanism, patient populations, etc.; \*\*Supplement to original Phase 3 filing in U.S. 0 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.1 Vamorolone Elevidys Dyne 251 ENTR-601-44 TTRV Change from Baseline Versus Placebo (rises/sec) Reported TTRV Competitive Comparisons • Phase 3 trials using TTRV as the primary endpoint: Novartis: del-zota, Phase 3 (initiating); Solid Biosciences: SGT-003, Phase 3 (ongoing); Roche: Elevidys, Phase 3 (to initiate in EU) Phase 2b\* Phase 3\*\* Phase 1/2 ENTR-601-44's TTRV versus placebo is superior to reported numbers from steroids, gene therapy and second-generation exon skipping therapies Phase 1/2 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img024.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ELEVATE-44-201: Pharmacokinetics and Biomarkers |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img025.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;May 2026 Lower-than-expected plasma exposures resulted in lower-than-expected exon skipping and dystrophin expression AUC: Area under the curve (proportions are approximate); 1.Healthy normal volunteer, single dose 6 mg/kg, 2.Pediatric DMD participants following third dose of 6 mg/kg every 6 weeks (similar, proportionally lower levels seen in juvenile NHP 55 week study); Note: As biopsies were taken 6 weeks post-final dose, muscle concentration levels were 10-fold below projected peak, in line with plasma concentration and expectations. Cmax (ng/mL) AUC (hr\*ng/mL) Adult (HNV) Pediatric (Cohort 1 patients) 25 Originally expected participant exposures, based on HNV1 and adult NHP exposures Actual participant exposure observed2 4.58 5.40 4.00 6.36 0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 Placebo Baseline Placebo D127 6 mg/kg Baseline 6 mg/kg D127 Mean Percent MHC Normalized Dystrophin 1.34 1.76 2.66 4.97 0.00 1.00 2.00 3.00 4.00 5.00 6.00 Placebo Baseline Placebo D127 6 mg/kg Baseline 6 mg/kg D127 Mean Percent Exon Skipping Percent Exon Skipping Percent MHC Normalized Dystrophin 2.31% Increase 2.36% Increase Lower Cmax and AUC observed in pediatric participants when compared with healthy adults ~60% of Adult ~40% of Adult Cmax (ng/mL) A linear (or better) increase in exposure is expected in Cohort 2 at 12 mg/kg which should result in substantially higher dystrophin levels and continued muscle function  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img026.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ENTR-601-44: Mechanistic Rationale |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img027.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;May 2026 Source: Servais L, et al. ICNMD 2026. Healthy muscle The DMD challenge: Muscle damage and impaired repair An ideal treatment is regenerative – replacing damaged, dystrophic muscle with healthy muscle; This requires satellite cell correction which then promotes asymmetric differentiation DMD muscle lacking dystrophin • Muscle fibers susceptible to damage • Stem cells and regeneration impaired • Muscle replaced with fat and scar tissue • Dystrophin supports stabilizing and repairing muscle fibers and stem cell replenishment and function The dystrophin "double hit" results in a decline in function • Lack of dystrophin results in muscle damage • Lack of dystrophin also results in the inability to repair and regenerate new fibers • Lack of normal regeneration results in the replacement of muscle with fat and fibrosis Satellite (stem) cells require dystrophin to efficiently promote muscle regeneration • Deficit inhibits asymmetric differentiation and activation, thus impairing regeneration 27 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img028.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;May 2026 Enhanced satellite cell activity would result in the regeneration of healthy fibers and the stabilization of the overall muscle; In turn, this may convert into greater strength, as measured by TTRV D2-mdx: Dystrophic mouse model; D2-mdx mice were treated with 3 IV doses of EEV-PMO administered every six weeks; Gastrocnemius was collected 12 weeks after the third dose and analyzed by immunohistochemistry; Data presented at International Conference on Muscle Wasting 2025; CK: Creatine kinase; Q6W: Every 6 weeks. Entrada differentiation • Immunohistochemistry data demonstrates PMO in satellite cells and newly regenerated centrally nucleated fibers 12 weeks post-washout after 3 Q6W doses (D2-mdx mice) Antibody and gene therapy competitors • No transferrin receptor expressed on these cells so the antibodies cannot reach them • AAV-enabled gene therapies lack ability to efficiently reach satellite cells which limits response durability Immunohistochemistry data demonstrates PMO in satellite cells and newly regenerated centrally nucleated fibers 12-weeks post-washout after 3 Q6W doses (D2-mdx mice) EEV-enabled stem cell uptake implies the potential for the return of healthy muscle and function 28 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img029.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Myotonic Dystrophy Type 1 (DM1) |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img030.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;May 2026 30 DM1 partnership established with Vertex in Q1 2023 • Entrada received an upfront payment of $224M and an equity investment of $26M upon initiation of the collaboration • Agreement provided for up to $485M for the achievement of milestones • Tiered royalties on future net sales VX-670 differentiation • Unlike antibody-based approaches, VX-670's targeted and specific blocking of pathogenic CUG repeats drives global transcriptome correction while preserving healthy DMPK levels • Satellite cell uptake may improve outcomes as CUG repeat length correlates with progenitor cell activation, proliferation and differentiation\* Vertex advancing a placebo-controlled Phase 1/2 clinical program at over 25 global sites • MAD portion of the clinical study to assess safety and efficacy is on track to read out in the second half of 2026 • Open-label extension study is enrolling • Same EEV utilized for VX-670 as in DMD franchise DM1: A transformational partnership with Vertex \*Hasuike et al., Front. Genet., March 2022; MBNL: Muscleblind-like proteins; CUG repeat: Repeating sequence of cytosine, uracil and guanine in RNA; DMPK: Dystrophia myotonica protein kinase. No disease-modifying treatments are currently available for the more than 110,000 people in the U.S. and Europe living with DM1 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img031.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inherited Retinal Diseases (IRDs) |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img032.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Addressing areas of high unmet need in IRDs with new oligonucleotide-based therapeutics May 2026 Usher Syndrome Type 2A (USH2A) • An inherited eye condition caused by changes in the USH2A gene • In some patients, mutations in exon 13 prevent production of the usherin protein • Without usherin, photoreceptors (the light-sensing cells in the eye) gradually degenerate • Lack of usherin leads to vision loss in early adulthood and legal blindness in mid-adulthood • No disease-modifying treatments are currently available that can slow or stop disease progression About ENTR-801 • Proprietary exon 13 skipping therapy designed to restore functional usherin protein production with the goal of preserving photoreceptor health and function • Demonstrated robust exon skipping and usherin protein production, with the potential for quarterly dosing IVT • IND-enabling studies will be initiated and clinical strategies will be shared in 2026 • ~15,000 patients in the U.S. and Europe are exon 13 skipping amenable\* Note: IRD: Inherited Retinal Disorders; \*Delmaghani et al., Hum Genet., Apr. 2022; Sanjurjo-Soriano et al., HGG Advance, Oct. 2023; Su et al., Front Aging Neurosci., Aug. 2022; IVT: Intravitreal. 32 Low Dose High Dose Entrada's first IRD clinical candidate, ENTR-801, will target Usher syndrome type 2A; Addressable population is ~15,000 patients\* in the U.S. and Europe with no approved therapeutics Duration of Truncated Usherin Protein Generation in phUSH2A WT Mice |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img033.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2026 Inflection Points  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img034.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;May 2026 ELEVATE-44-201 Cohort 1 open-label functional data, Cohort 2 dystrophin and functional data and ELEVATE-45-201 Cohort 1 data represent additional 2026 catalysts • All ELEVATE-44-201 Cohort 1 participants have rolled over into the open-label portion of the study ▪ Placebo participants crossed over into treatment via the open-label period ▪ Company expects continued functional response with additional measurements collected during open-label period ▪ Completion of open-label period expected by year-end 2026 • ELEVATE-44-201 Cohort 2 at 12 mg/kg continues to enroll with readout expected by year-end 2026 ▪ Higher levels of plasma and muscle exposure expected ▪ Concomitant increases in exon skipping and dystrophin production are expected ▪ Continued functional responses expected at higher doses • ELEVATE-45-201 Cohort 1 at 5 mg/kg fully enrolled with readout expected in mid-2026 2026 inflection points 34 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img035.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note: All references in this presentation regarding planned regulatory filings and clinical study designs are subject to ongoing discussion with regulatory authorities; \*Based on May 2026 current operating plans and ~$255M in cash, cash equivalents and marketable securities as of March 31, 2026. 35 VX-670 MAD portion of global Phase 1/2 ongoing Multiple 2026 near-term value drivers anticipated across expanding pipeline of intracellular therapeutics ENTR-601-45 Multiple clinical study sites activated in U.K. and EU FPD with Cohort 1 data expected mid-2026 ENTR-601-44 Global Phase 1/2 MAD study ongoing Cohort 1 data demonstrated safety, dystrophin production and functional improvement Cohort 2 data expected by year-end 2026 ENTR-601-45 Global Phase 1/2 MAD study ongoing Cohort 1 data expected mid-2026 VX-670 Vertex is on track to share results in H2 2026 ENTR-601-51 Global regulatory filings expected following a review of data from the ongoing DMD clinical studies Cash runway into Q3 2027\* ENTR-601-50 Received authorization for Phase 1/2 MAD study (U.K.) EU regulatory filing expected following a review of data from the ongoing DMD clinical studies ENTR-801 Initial IRD candidate focused on Usher syndrome type 2A Additional data and clinical plans will be shared in 2026 Second IRD candidate declaration in H2 2026 Pipeline Expansion Next-generation EEVs for neuromuscular expansion Ocular expansion into larger disease areas Range of undisclosed diseases and modalities |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img036.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Appendix |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img037.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EEV Platform |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img038.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Understanding EEV endosomal escape advantages May 2026 38 Unique pH-dependent membrane binding affinity enhances EEV endosomal escape Sahni, A. et al. ACS Chem. Biol. 2021; CPP: Cell-penetrating peptide. • EEVs have a higher affinity to phospholipids compared to traditional linear CPPs; The interaction of EEVs with phospholipids is pH-dependent • The specific interaction of EEVs with the endosomal membrane facilitates the escape of EEVs from early endosomes, as demonstrated by the correlation between endosomal escape efficiency and endosomal membrane binding affinity This results in "Saddle Splay" Binding of Arg-rich peptides induces negative curvature Post Collapse DextranAlexa Merge EEV12TMR Nucleation Zones Binding to Endosome Membrane Budding Positive curvature Negative curvature Insertion of hydrophobic groups induces positive curvature High Intracellular Uptake ~90% uptake Unique Budding Mechanism Conserves endosomal integrity pH 7.4 pH ~6.5 pH ~6.5 Efficient Endosomal Escape ~25-50-fold increase in endosomal escape vs. other competitive approaches Concept Mechanism Visualization |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img039.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;R6-PMO EEV-PMO 0 10 20 30 40 50 60 70 80 90 100 Exon Skipping (%) \* • PMO sequences are the same, cell penetrating peptides are different (linear vs. cyclic) • EEV-PMO significantly improved exon skipping after 3 days in mdx mice as compared to competitive R6-PMO EEV Optimization PMO Optimization • EEVs are the same, PMO sequences are different (casimersen vs. Entrada proprietary) • Proprietary PMO significantly improved exon skipping after 3 days in mdx mice as compared to competitive casimersen sequence May 2026 Entrada optimizes both the EEV delivery vehicle and the active conjugate to create best-in-class medicines \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, \*\*\*\*p<0.0001; relative to saline; Concentrations provided are PMO equivalent; Data presented at 2024 World Muscle Society conference. 39 In the below DMD example, Entrada has optimized the EEV and the PMO sequence; The data represents the superiority of each component against other approaches and sequences Saline EEV-PMO45 (45 mg/kg) ENTR-601-45 (45 mg/kg) 0 10 20 30 40 50 60 70 80 90 100 Exon Skipping (%) ✱✱ ✱✱✱✱ ✱✱✱✱ Casimersen PMO Sequence Proprietary PMO Sequence Casimersen PMO Sequence Proprietary PMO Sequence |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img040.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DMD Approach |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img041.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inflammation Necrosis Fibrogenesis Atrophy Entrada addresses the underlying cause of DMD and restores dystrophin in muscle fibers and muscle stem cells May 2026 Adapted from Front. Cell Dev. Biol., 18 August 2021; Sec. Molecular and Cellular Pathology; Volume 9, 2021; 1.No other exon skippers nor gene therapy fit all the disease-modifying criteria; 2.ENTR-601-44 data. DMD Gene Mutation Dysfunctional Dystrophin Membrane Damage Calcium Dysregulation Progenitor Senescence Oxidative Stress 2. Supportive care agents only address downstream biology • Myosin(i), AAK1(i), HDAC(i) may potentially enhance disease-modifying therapies and complement dystrophin restoration • Mechanisms include membrane protection/repair and stem cell proliferation • Symptomatic care, led by steroids, have served as standard of care despite long-term tolerability and safety concerns 1. Disease-modifying agents address the root cause of morbidity and mortality • Double-digit high-quality dystrophin production protects healthy muscle and restores regenerative capacity • Must be safe, potent, reach both mature and progenitor cells, be infrequently dosed, be redosable and dosing is weight based to meet the needs of a growing child • Entrada is developing the only disease-modifying agents with the potential to meet ALL of the above1 The Duchenne Disease Cascade Current and Emerging Treatment Options Signaling Perturbation Mitochondrial Dysfunction Entrada's next-generation exon skippers • Established safety at a therapeutic dose of 6 mg/kg with escalation to 12 mg/kg underway2 • Expected to provide durable and significant access to skeletal and cardiac muscle • Target progenitor cells (satellite) needed to regenerate muscle and provide functional benefit • Flexible to dose escalate and redose Final Common Pathway 41 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img042.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competitive Comparison |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img043.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Design Dose Uptake Target engagement Anti-TfR1-mAb-PMO (exon 44) Novartis/Avidity Anti-TfR1-Fab-PMO (exon 51) Dyne Full-length antibody ~150 kDa TfR1 specific deliver; Non-cleavable linker Fragment antibody ~50 kDa TfR1 specific delivery; Cleavable linker Large conjugate doses 5 mg/kg PMO (registrational dose) + ~23 mg/kg mAb = ~28 mg/kg whole drug dose1 Large conjugate doses 20 mg/kg PMO (registrational dose) + undisclosed mg/kg Fab = undisclosed mg/kg whole drug dose2 Apparent limit on dose response No increase in dystrophin from 5 to 10 mg/kg PMO dose in DMD exon 44 patients: 25% vs. 26%4,5 Apparent limit on dose response No increase in dystrophin from 10 to 20 mg/kg PMO dose in DMD exon 51 patients: 2.97% vs. 3.14%2,4 No enhanced endosomal escape Once dissociated from the mAb in the lysosome, the unconjugated PMO escapes at <2% efficiency6 No enhanced endosomal escape Once dissociated from the Fab in the endosome, the unconjugated PMO escapes at <2% efficiency6 EEV therapies are expected to show superior dystrophin production and dose-dependent increases in therapeutic index May 2026 43 TfR1: Transferrin receptor 1; 1.Etxaniz et al., Nucleic Acid Res., 2025; 2.Dyne corporate materials from DELIVER Clinical Update investor call September 2025; 3.Total mean exon skipping; Entrada internal data from Phase 1 SAD study of ENTR-601-44 in HNV; 4.Unadjusted dystrophin, mean change from baseline; 5.Avidity corporate materials from del-zota Topline Data investor call March 2025; 6.Dowdy et al., Nucleic Acid Ther., 2022. EEV-PMO Entrada Cyclic, arginine-light peptide 2.6 kDa Tissue-specific delivery; Increases stability and half-life Low conjugate doses ~5 mg/kg PMO + 1 mg/kg EEV = 6 mg/kg whole drug (ELEVATE-44-201 Cohort 1 dose) No limit on dose response seen 48.3% increase in exon skipping from 3 to 6 mg/kg whole drug dose in HNV3 Enhanced endosomal escape ~25-fold increase in endosomal escape vs. other competitive approaches A 25-50-fold improvement in endosomal escape, novel PMO sequences, non-linear increases in PK/PD, satellite cell uptake and lower whole drug requirements compared to antibody-based therapies |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img044.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharmacokinetic Modeling |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img045.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;May 2026 Lower Cmax and AUC observed in juvenile humans and NHPs; A linear (or better) increase in exposure is expected in Cohort 2 at 12 mg/kg (double dose = double exposure) Predictive pharmacokinetics \*Healthy normal volunteer, single dose 6mg/kg, pediatric DMD patients following third dose; \*\*Adult: 13-week 25 mg/kg repeat dose study, Q6W, 3 doses; Juvenile: 55-week 20 mg/kg repeat dose study, Q6W,10 doses. Cmax (ng/mL) AUC (hr\*ng/mL) Adult (HNV) Juvenile (Cohort 1 patients) Human (HNVs and Patients)\* Cmax (ng/mL) AUC (hr\*ng/mL) Adult (NHP) Juvenile (NHP) Non-Human Primate\*\* 45 ~60% of Adult ~40% of Adult ~50% of Adult ~50% Adult Proportional Difference (Juvenile = ~60% of Adult) Cmax (ng/mL) Cmax (ng/mL) |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img046.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;May 2026 46 Juvenile NHP Plasma Concentration and Exon Skipping Expected AUC in Cohort 1 • Juvenile NHP data suggest a right-shifted double-digit dystrophin expectation starting at 12 mg/kg in Cohort 2 • As the exposure to exon skipping relationship has not changed, updated projections indicate significantly increased exon skipping and dystrophin expression expected in Cohorts 2 and 3 • Cohorts 2 and 3 dystrophin levels will be assessed for registrational potential, when combined with observed functional outcomes NHP data from 55 weeks, QW6, 10 doses, chronic juvenile toxicology study. Cohort 1 Participant Data Extrapolation Juvenile NHP data suggest an increase of AUC should result in substantially higher dystrophin levels and increases in muscle function Improved, predictive modeling based on new data point to higher dystrophin levels in Cohorts 2 and 3 Cohort 2 Model Cohort 3 Model % Exon Skipping Plasma Concentration (AUC, hr\*ng/mL) 0% 10% 20% 30% 40% 50% 60% 70% - 20,000 40,000 60,000 80,000 100,000 120,000 5 mg/kg 20 mg/kg 30 mg/kg Expected AUC in Cohort 1 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img047.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DMD Functional Data Preclinical Models |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img048.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preclinical data support potential for best-in-class clinical profile for ENTR-601-45 May 2026 48 Data are shown as mean ± SD; \*p ≤ 0.05; \*\*p ≤ 0.01; \*\*\*p ≤ 0.001; \*\*\*\*p ≤ 0.0001; 25 mg/kg correlates to ~5 mg/kg human equivalent dose (HED), 50 mg/kg correlates to ~10 mg/kg HED, 75 mg/kg correlates to ~15 mg/kg HED; Data presented at the 2024 World Muscle Society conference. • Active and vehicle del44hDMD.mdx mice, n=5 per cohort, EEV-PMO-45 (Q6W x 3 doses); Control saline treated hDMD.mdx mice, n=10 (Q6W x 3 doses) • Skipping (ddPCR) and dystrophin production (JESS) is significantly increased 6 weeks after the third dose of ENTR-601-45 (gastrocnemius muscle shown) Exon Skipping Dystrophin Restoration Functional Correction ENTR-601-45 0 20 40 60 80 100 % H u m a n E x o n 4 5 S kip pin g \*\* \*\*\*\* \*\*\*\* Dose in mg/kg 0 20 40 60 80 100 D y stro p hin Re storatio n (%) N orm alize d to h D M D.m dx \*\*\*\* \*\* \* Dose in mg/kg 0 20 40 60 80 100 % D y stro p hin P o sitiv e Fib ers \*\*\*\* \*\*\*\* \*\*\*\* Dose in mg/kg 0 50 100 \*\*\*\* \*\*\*\* \*\*\*\* \*\*\* Dose in mg/kg Dose-dependent increase in exon skipping and dystrophin expression correlates to complete functional correction % Force before injury |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img049.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dose-dependent and durable improvements in muscle function observed in del44hDMD.mdx mice May 2026 49 del44hDMD.mdx mice were treated with three Q6W IV injections of ENTR-601-45 or vehicle; ECC-induced muscle force loss generated by repeated eccentric force (ECC) contraction of the gastrocnemius muscle was assessed 5 weeks (left/center) or 4 and 8 weeks (right) after the third dose; Data (mean ± standard deviation) shown across 10 ECC contractions normalized into a percentage of the initial force before any ECC contractions and as the percentage of force retained after the tenth contraction; Vehicle-treated hDMD.mdx mice were used as a control group for normal muscle function; One-way ANOVA (Analysis of variance) was used for statistical comparison to vehicle-treated del44hDMD.mdx mice; \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001 vs. vehicle; Data presented at the 2024 World Muscle Society conference. Skeletal Muscle Membrane Stability Stability After Washout ENTR-601-45 Dose-dependent increase in percent force retention following 10 contractions; Increase maintained for at least 8 weeks after the third Q6W dose of ENTR-601-45 % Force before injury % Force before injury |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img050.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Efficacy of ENTR-601-50 in exon 50 skipping amenable mice Single dose of ENTR-601-50 produced robust human DMD exon 50 skipping and dystrophin; Translated into improvements in muscle function within 2 weeks post-dose ENTR-601-50 Exon Skipping and Dystrophin in the Gastrocnemius Percent Force After 10 Contractions del51hDMD.mdx mice were treated with a single IV injection of ENTR-601-50 or vehicle. Human DMD exon 50 skipping (top) and dystrophin protein expression (bottom) were analyzed in the gastrocnemius, diaphragm and heart 2 weeks post-dose; Percent dystrophin protein restoration is normalized to total protein and normalized to hDMD.mdx controls; Data shown as mean ± standard deviation; One-way ANOVA was used for statistical comparison; ECC-induced muscle force loss generated by repeated ECC contraction of the gastrocnemius muscle was assessed 2 weeks after dosing. Data (mean ± standard deviation) are shown across ten ECC contractions normalized as the percentage of force retained after the tenth contraction; Data presented at the 2025 World Muscle Society conference; IV: Intravenous. May 2026 50 0 50 100 150 % F orc e b efore injury ✱✱✱✱ ✱✱ ✱✱✱✱ del51hDMD.mdx mice Vehicle 25 45 0 10 20 30 40 D y stro p hin re storatio n (%) N orm aliz e d to h D M D m. dx del51hDMD.mdx mice \*\*\*\* Vehicle 25 45 0 20 40 60 % E x o n 5 0 S kip pin g del51hDMD.mdx mice \*\*\*\* \*\*\*\* 45 mg/kg ENTR-601-50 25 mg/kg ENTR-601-50 del51hDMD.mdx vehicle 45 mg/kg ENTR-601-50 25 mg/kg ENTR-601-50 del51hDMD.mdx vehicle \*\*\* ENTR-601-50_45 mg/kg ENTR-601-50_25 mg/kg ENTR-601-50_15 mg/kg del51hDMD.mdx vehicle hDMD.mdx vehicle |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm2614944d1_ex99-1img051.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Learn more at EntradaTx.com |

---